埃替拉韦

溶解度:Unknown

储存条件:-20C 2 years

生物活性

Elvitegravir, a quinolone carboxylic acid strand-transfer specific inhibitor that displayed an IC50 of 7 nM against IN and an antiviral EC90 of 1.7 nM in the presence of NHS. In terms of pharmacokinetics, in rat and dog elvitegravir displayed a 34% and 30% bioavailability, a 2.3 h and 5.2 h half-life, and a 8.3 mL/min/kg and 17 mL/min/kg clearance, respectively.

参考文献

1. Erik Serrao, Srinivas Odde, et al. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25 2. Kearney B, Mathias A, Zhong L. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatmentnaïve and experienced patients [abstract]. International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon 2006.